Minerva Neurosciences to Host In-Person KOL Event on Roluperidone
Minerva Neurosciences plans an in-person key opinion leader event to discuss roluperidone for negative symptoms of schizophrenia.
Related stories
Klabin Sees El Niño Pressuring Operations Through Q1 2027
Klabin sees El Niño pressuring its operations through the first quarter of 2027.
L impact | EQUITY | Oct 29, 2026, 02:41 PM UTC
Garrett Motion shares rise 5.2% after Q3 earnings
Garrett Motion shares rose 5.2% in Thursday trading after the company reported Q3 earnings and higher net sales.
M impact | EQUITY | Oct 29, 2026, 02:40 PM UTC
Nextensa Sells Luxembourg Office Building for EUR43.5 Million
Nextensa announced the sale of a Luxembourg office building to Centre Hospitalier de Luxembourg for EUR43.5 million.
L impact | EQUITY | Oct 29, 2026, 02:40 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Revenue of RMB 14.63 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
SUMMI Group Delays FY26 Annual Results Publication
SUMMI Group’s FY26 annual results publication is delayed due to audit procedures.
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC
Shenzhen Longsys Electronics Reports Quarterly Net Profit of RMB 3.74 Billion
M impact | EQUITY | Oct 29, 2026, 02:39 PM UTC